- Home
- SYBX vs EDSA Comparison
SYBX vs EDSA Comparison
Compare SYBX & EDSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SYBX
- EDSA
- Stock Information
- Founded
- SYBX N/A
- EDSA 2015
- Country
- SYBX United States
- EDSA Canada
- Employees
- SYBX N/A
- EDSA N/A
- Industry
- SYBX Biotechnology: Pharmaceutical Preparations
- EDSA Biotechnology: Pharmaceutical Preparations
- Sector
- SYBX Health Care
- EDSA Health Care
- Exchange
- SYBX Nasdaq
- EDSA Nasdaq
- Market Cap
- SYBX 20.0M
- EDSA 18.6M
- IPO Year
- SYBX N/A
- EDSA N/A
- Fundamental
- Price
- SYBX $1.77
- EDSA $2.74
- Analyst Decision
- SYBX
- EDSA Strong Buy
- Analyst Count
- SYBX 0
- EDSA 2
- Target Price
- SYBX N/A
- EDSA $13.00
- AVG Volume (30 Days)
- SYBX 35.2K
- EDSA 136.4K
- Earning Date
- SYBX 11-11-2025
- EDSA 12-12-2025
- Dividend Yield
- SYBX N/A
- EDSA N/A
- EPS Growth
- SYBX N/A
- EDSA N/A
- EPS
- SYBX N/A
- EDSA N/A
- Revenue
- SYBX N/A
- EDSA N/A
- Revenue This Year
- SYBX N/A
- EDSA N/A
- Revenue Next Year
- SYBX N/A
- EDSA N/A
- P/E Ratio
- SYBX N/A
- EDSA N/A
- Revenue Growth
- SYBX N/A
- EDSA N/A
- 52 Week Low
- SYBX $0.90
- EDSA $1.55
- 52 Week High
- SYBX $1.96
- EDSA $4.49
- Technical
- Relative Strength Index (RSI)
- SYBX 56.70
- EDSA 57.82
- Support Level
- SYBX $1.64
- EDSA $2.59
- Resistance Level
- SYBX $1.87
- EDSA $2.95
- Average True Range (ATR)
- SYBX 0.09
- EDSA 0.21
- MACD
- SYBX -0.00
- EDSA 0.01
- Stochastic Oscillator
- SYBX 64.91
- EDSA 64.23
About SYBX Synlogic Inc.
Synlogic Inc is a biopharmaceutical company focuses on rare metabolic disorders, with a lead program in phenylketonuria (PKU) and homocystinuria (HCU). The company's pipeline includes therapeutics for enteric hyperoxaluria, gout, and cystinuria. Using a proprietary approach, the company engineer GI-restricted, oral medicines from well-characterized probiotics. These drug candidates target specific biological pathways, leveraging Escherichia coli Nissle 1917 for consistency and safety. Engineered to be non-colonizing and reversible, the company offer oral administration, simplifying shipping and storage. The company operates in one segment-discovery and development of Synthetic Biotics-pioneering transformative treatments for serious diseases.
About EDSA Edesa Biotech Inc.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.